CelluTarget · Multifocal Motor Neuropathy · Treatments
✓ Standard of Care

Antiplatelet therapy (aspirin, clopidogrel, ticagrelor)

1
Evidence entries
0
Clinical trials
1
High-confidence findings
Overview
Treatment Details
Mechanism of Action
Inhibits platelet aggregation to reduce risk of thrombus formation at sites of plaque rupture. Aspirin irreversibly inhibits COX-1; clopidogrel and ticagrelor block ADP-mediated platelet activation via P2Y12 receptor. Standard in all patients with established CAD.
Dosing Notes
Low-dose aspirin (75–100 mg daily) for secondary prevention. Dual antiplatelet therapy (DAPT) with clopidogrel or ticagrelor for 12 months post-ACS or stenting.
Treatment Type
pharmaceutical
Clinical Evidence
What the Evidence Shows
Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.
High: Supported by multiple robust studies or regulatory approval
Moderate: Supported by limited controlled studies or consistent case series
Low: Based on case reports, expert opinion, or early-phase data only
High ConfidenceSupported by multiple robust studies or regulatory approval
Aspirin and P2Y12 inhibitors are standard secondary prevention in all CAD patients; DAPT for 12 months post-ACS reduces recurrent MI and stent thrombosis.
Verified Jul 2026
Peer Reviewed
Medscape: Coronary Artery Atherosclerosis Treatment & Management
View source ↗
Clinical Trials
Linked Trials
No clinical trials linked to this treatment yet.